DHR · Danaher Corporation

Danaher reported solid first quarter 2026 results with revenue growth of 3.5% year-over-year to $6.0 billion, driven by strength in Bioprocessing and better-than-expected performance in Life Sciences, partially offset by a lighter-than-typical respiratory season at Cepheid. The company delivered nearly 10% adjusted EPS growth, with non-GAAP adjusted diluted EPS reaching $2.06, up 9.5% from the prior year. Management highlighted strong execution that enabled acceleration of innovation and productivity gains. The company raised its full-year 2026 adjusted diluted EPS guidance to $8.35-$8.55 from the previous $8.35-$8.50 range, reflecting confidence in continued performance. For the second quarter, Danaher anticipates non-GAAP core revenue will increase in the low-single digit percent range year-over-year. The company also announced its intention to acquire Masimo Corporation, a leading provider of pulse oximetry and patient monitoring solutions, which management believes presents opportunities to enhance performance through Danaher's Business System and global scale. Management noted that strong free cash flow generation provides additional capacity for value-creating capital deployment.